Diverging effects of human recombinant anti-hepatitis C virus (HCV) antibody fragments derived from a single patient on the infectivity of a vesicular stomatitis virus/HCV pseudotype

Roberto Burioni, Yoshiharu Matsuura, Nicasio Mancini, Hideki Tani, Tatsuo Miyamura, Pietro E. Varaldo, Massimo Clementi

Research output: Contribution to journalArticle

Abstract

Hepatitis C virus (HCV) is the major causative agent of blood-borne non-A, non-B hepatitis. Although a strong humoral response is detectable within a few weeks of primary infection and during viral persistence, the role played by antibodies against HCV envelope glycoproteins in controlling viral replication is still unclear. We describe how human monoclonal anti-HCV E2 antibody fragments isolated from a chronically HCV-infected patient differ sharply in their abilities to neutralize infection of HepG2 cells by a vesicular stomatitis virus pseudotype bearing HCV envelope glycoproteins. Two clones were able to neutralize the pseudotype virus at a concentration of 10 μg/ml, while three other clones completely lacked this activity. These data can explain the lack of protection and the possibility of reinfection that occur even in the presence of a strong antiviral antibody response.

Original languageEnglish
Pages (from-to)11775-11779
Number of pages5
JournalJournal of Virology
Volume76
Issue number22
DOIs
Publication statusPublished - 2002

ASJC Scopus subject areas

  • Immunology

Fingerprint Dive into the research topics of 'Diverging effects of human recombinant anti-hepatitis C virus (HCV) antibody fragments derived from a single patient on the infectivity of a vesicular stomatitis virus/HCV pseudotype'. Together they form a unique fingerprint.

  • Cite this